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Description of the method used for evidence preparation
The members of the Comissão de Espondiloartrites da Sociedade 
Brasileira de Reumatologia (Commission on Spondyloarthritis of 
the Brazilian Society of Rheumatology, SBR) 2010-2012 took 
part in the Evidence Preparation Course given by the Asso-
ciação Médica Brasileira (Brazilian Medical Association, AMB) in 
São Paulo in the fi rst semester of 2011. The questions were 
fi nally concluded at a meeting of the Commission on Spon-
dyloarthritis held on 15 October 2011 in Florianópolis (SC, 
Brazil), during the 18th Southern Cone Rheumatology Meeting 
and were later approved by all the coordinators of the Bra-
zilian Spondyloarthritis Registry. The 15 clinical questions 
considered to be relevant were structured using the P.I.C.O. 
method (patient; intervention or indicator; comparison; out-
come). The literature search was conducted by searching the 
databases MEDLINE, EMBASE, SciElo/Lilacs, and the Cochrane 
Library through February, 2012 (Appendix). Critical assess-
ment of the evidence in the selected articles was performed 
using the Jadad score. Next, the answers to the questions in-
cluded in the Recommendations were elaborated, and all the 
selected references exhibit the corresponding grade of recom-
mendation and strength of scientifi c evidence. The references 
were updated through August, 2012, entered into a single fi le 
by the coordinator, and sent to the co-authors in two succes-
sive rounds for preparation of the fi nal version.
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C: Case reports (uncontrolled studies).
D: Opinion that is not substantiated by critical evaluation, 
based on consensus, physiological studies or animal 
models.
Objective
To establish recommendations for the management (classi-
fi cation and evaluation criteria by magnetic resonance and 
genetics) of spondyloarthritis and for the treatment of anky-
losing spondyloarthritis.
Introduction
The concept of seronegative spondyloarthropathies was es-
tablished in 1974, when British researchers Moll and Wright 
proposed the grouping of certain diseases that had been, until 
then, considered completely different from each other but that 
in fact had several common features. Such characteristics en-
compassed clinical aspects (infl ammatory axial pain associated 
with arthritis, predominant in the large joints of the lower limbs, 
and peripheral enthesopathy), radiological aspects (sacroiliitis), 
and laboratory aspects (seronegativity for rheumatoid factor 
because, until the 70’s, some researchers considered ankylosing 
spondylitis (AS) to be an axial component of rheumatoid arthri-
tis) in individuals with a genetic predisposition (linked to the 
histocompatibility antigen HLA-B27). This set consisted of AS, 
psoriatic arthritis, reactive arthritis, and enteropathic arthropa-
thies (associated with infl ammatory bowel disease).1 
In 2009, specialists from the Assessment on Spondyloarthritis 
International Society (ASAS) proposed changing the name of the 
group to spondyloarthritis (SpA), emphasising the axial (“spon-
dylo”) and peripheral (“arthritis”) components of the diseases 
in this group. At the same time, the classifi cation criteria were 
proposed for axial SpA2,3 and, subsequently, peripheral SpA.4 The 
changes also included a description of the criteria for the diagno-
sis of sacroiliitis by magnetic resonance (MR).5 These new diag-
nostic criteria and classifi cations contributed to a better charac-
terisation of the broad spectrum of diseases in this group.
Among the diseases in the SpA group, without a doubt, AS 
is the most common and best represents the set of classical 
manifestations of SpA. A signifi cant number of patients with an 
undifferentiated SpA diagnosis, which could initially be termed 
non-radiographic axial SpA or peripheral SpA, evolve to AS if 
followed long-term.6 Therefore, knowledge regarding the clas-
sifi cation criteria for SpA and AS is important in the diagnosis 
and monitoring of patients in this group. With the advent of new 
treatments for AS, early diagnosis and the institution of a spe-
cifi c treatment is necessary to improve the quality of life of these 
patients, who are usually young adults in the prime of their pro-
ductive lives.
1. What are the best criteria for an individual to 
be considered affected by a spondyloarthritis?
Axial spondyloarthritis
The ASAS group conducted a Delphi study with the participa-
tion of its members to select the possible variables that should 
be assessed in patients with axial SpA. These variables were 
evaluated in a prospective study that included 647 patients with 
back pain lasting over three months without apparent cause or 
known diagnosis, with or without peripheral symptoms, whose 
symptoms started before the age of 45 years, followed up in 25 
universities of 16 countries. 
After statistical assessment, the criteria proposed were based 
on two main variables: sacroiliitis by imaging (hip radiograph or 
MRI) and the histocompatibility antigen HLA-B27. The presence 
of a main variable (sacroiliitis by imaging or HLA-B27 positive) 
and of one (when sacroiliitis by imaging) or two (when HLA-B27 
positive) criteria that are characteristic of SpA [infl ammatory 
back pain, peripheral arthritis, enthesitis, dactylitis, cutaneous 
psoriasis, Crohn’s disease or ulcerative colitis, good response to 
nonsteroidal anti-infl ammatory drugs (NSAID), family history of 
SpA, HLA-B27 positive, elevated C-reactive protein] are crucial 
for the patient to be classifi ed with axial SpA. The sensitivity of 
this criteria group is 82.9%, and the specifi city is 84.4%2,3(B).
Peripheral spondyloarthritis
The criteria from the ASAS group for peripheral SpA are as 
follows: peripheral joint manifestations (arthritis, enthesitis, 
dactylitis) associated with one or more variables (psoriasis, in-
fl ammatory bowel disease, previous infection, HLA-B27, uve-
itis, sacroiliitis imaging) or two or more parameters (arthritis, 
enthesitis, dactylitis, infl ammatory low back pain in the past, 
family history of spondyloarthritis) in patients with peripheral 
manifestations starting prior to 45 years of age. The sensitivity 
of these criteria is 79.5%, and the specifi city is 83.3%. Thus, in a 
clinical setting with a high prevalence of peripheral SpA (66.2%), 
the use of these diagnostic criteria increases the probability of a 
diagnostic certainty to 90%4(B).
Recommendation 1
Currently, the best criteria that allows for the classifi cation of 
a patient as having axial or peripheral SpA is the one proposed 
by the ASAS. 
2. What is the role of MRI in the initial evaluation of 
axial spondyloarthritis?
Diagnosis
The use of MRI, through components such as oedema, erosion, 
fat infi ltration, and ankylosis, allows for the diagnosis of axial 
SpA with sensitivity and specifi city of 90% and 97%, respectively, 
conferring a positive likelihood ratio of 30 and, therefore, a 97% 
diagnostic certainty when positive and 91% when negative7(A).
The diagnosis of more than fi ve fatty Romanus lesions (high 
signal on T1-weighted MRI) is associated with an axial SpA di-
agnosis in patients with low back pain, with an 86% certainty 
(likelihood ratio: 12.6)8(B).
Prognosis
The combination of severe sacroiliitis, diagnosed by MRI, with a 
positive HLA-B27 predicts the development of future AS (eight-
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year follow-up) with a sensitivity and specifi city of 62% and 
92%, respectively, with a positive post-test probability of 80% 
and a negative post-test probability of 83%. Signifi cant sac-
roiliitis, isolated, predicts the diagnosis with a positive post-
test probability of 50% and a negative post-test probability of 
84%9(A).
The persistence of active infl ammation in the shiny cor-
ners, diagnosed by MRI in AS patients receiving anti-TNFα 
treatment during two years of follow-up, predicts a 14.9% in-
crease (number needed to harm, NNH: 7) in the risk of devel-
oping new syndesmophytes. In cases where the infl ammation 
has been treated with anti-TNFα, this risk increases by 11.4% 
(NNH: 8)10(A).
A two- to seven-year follow-up of patients with axial SpA 
and the evaluation of sacroiliac changes (Danish score – ero-
sion, oedema, and fatty infi ltration) by MRI showed that chron-
ic changes increase the risk in AS patients. Activity scores ≥ 2, 
chronic ≥ 1, erosion ≥ 1, and of fatty infi ltration ≥ 4 at the be-
ginning of follow-up are associated with the chronicity of the 
sacroiliac changes with a diagnostic accuracy of 74%, 77%, 79%, 
and 68%, respectively11(A).
Recommendation 2
In patients with axial SpA, magnetic resonance has diagnostic 
and prognostic importance.
3. When should HLA-B27 be requested in a patient 
with axial spondyloarthritis?
Axial spondyloarthritis
The prevalence of positive HLA-B27 in patients with axial SpA 
is increased by 38.2% compared with patients without axial 
SpA. HLA-B27 is one of the classifi cation criteria required, and, 
when associated with other variables (such as images and 
clinical criteria), it allows for the classifi cation of a patient as 
having axial SpA with a sensitivity and specifi city of 83.7% and 
83.3%, respectively, leading to a diagnostic certainty of 83% 
when positive and negative3(B).
Ankylosing spondylitis
In patients with AS, the prevalence of positive HLA-B27 can 
be 90.2%. Compared with negative HLA-B27 patients, the pa-
tients with AS have a longer disease duration, a 23.6% (NNH: 
4) increase in previous or current use of NSAIDs, and an 18.9% 
(NNH: 4) increase in the risk of biological indicators (ASAS cri-
teria). HLA-B27-positive patients may have a more severe dis-
ease, with an increase in ocular (38.9% vs. 12.5%), pulmonary 
(4.2% vs. 0%), and cardiac (4.3% vs. 0%) comorbidities associat-
ed with higher values of the functional index (Bath Ankylosing 
Spondylitis Functional Index, BASFI) and disease activity (Bath 
Ankylosing Spondylitis Disease Activity Index, BASDAI)12(B). 
The analysis of predictive factors of AS in patients with in-
fl ammatory low back pain shows that sacroiliitis diagnosed 
by MRI, when associated with positive HLA-B27, increases the 
specifi city and sensitivity of the diagnosis compared with im-
aging alone from 84% to 94% and 33% to 62%, respectively. A 
positive HLA-B27 alone is capable of predicting the disease 
with a 48% probability and can rule out the disease when nega-
tive with a probability of 88%13(A).
In the evaluation of AS patients sorted by age at disease on-
set (< 20 years of age, 21-30 years of age, 31-40 years of age, and 
> 40 years of age), a positive HLA-B27 is found in 94.6%, 90.2%, 
74.1%, and 61.2% of the patients, respectively. Thus, positive 
HLA-B27 is associated with a younger age of onset14(B).
The chance of the presence of the HLA-B27 gene in patients 
with familial AS is 344% higher than in patients with sporadic 
ankylosing spondylitis15(B).
Recommendation 3
HLA-B27 is particularly useful in determining prognosis, espe-
cially in AS patients and with regard to time of onset.
4. What is the evidence for the use of physical 
rehabilitation in patients with ankylosing 
spondylitis?
The treatment of AS patients based on postural rehabilitation 
and the rehabilitation of the fl exor and extensor musculature, 
according to the Global Postural Reeducation (GPR) method, 
or by means of 20 exercises (cervical, thoracic and lumbar 
mobility and fl exibility, stretching of fl exor musculature and 
strengthening of extensor musculature, and exercises for tho-
racic expansion) provides signifi cant improvement compared 
with pre-treatment, as measured using the Bath Ankylosing 
Spondylitis Metrologic Index (BASMI, which includes the Schö-
ber modifi ed test, cervical rotations, lumbar fl exion, and inter-
malleolar distance), BASDAI, and BASFI. A comparison between 
the two treatments showed better results with postural reha-
bilitation using GPR within a year of follow-up16,17(A).
AS patients undergoing regular rehabilitations programs 
for four weeks were subjected to evaluation after 28 weeks re-
garding their health (patient global assessment, pain, morning 
rigidity, BASFI, BASDAI, and fatigue) and the ASAS-IC (Assess-
ments in Ankylosing Spondylitis working group’s Improvement 
Criteria) criteria. The programs offer personalised evaluation 
of physical therapy, group exercises, passive therapy, relax-
ation, and patient education, with differences in two compo-
nents – resistance versus mobility. After 16 weeks, both forms 
of rehabilitation (resistance and mobility) showed signifi cant 
improvements in several variables (except BASDAI); however, 
the rehabilitation centred on mobility led to an increase in the 
proportion of patients achieving ASAS20 and ASAS40 to 27% 
(number needed to treat, NNT: 4) and 19% (NNT: 5), respectively, 
compared with resistance. In 28 weeks of follow-up, the results 
were greater in patients with dominance in the mobility com-
ponent. At 16 weeks, mobility increased the benefi ts as mea-
sured using the Schöber test (20% and 40%) in 18% and 19% of 
patients, respectively, and with respect to lateral fl exion (20% 
and 40%) in 37% and 36% of patients, respectively18(A). 
Recommendation 4
Rehabilitation programs benefi t AS patients, especially during 
the period in which the patients are undergoing rehabilitation. 
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Specifi c programs that focus on mobility improvement have 
shown superior results.
5. What is the evidence for the use of corticosteroids 
in patients with ankylosing spondylitis?
The comparison of two methylprednisone doses (375 mg vs. 1 
g intravenous for three days) in the treatment of AS patients 
not responding to NSAIDs demonstrated that thoracic and 
lumbar mobility, pain, and morning rigidity improved at both 
doses with no differences between the doses. Adverse events 
occurred in both groups, with the main events being dizziness, 
dry mouth, sleep disturbances, irritability, impotence, and 
weight gain19(A). Methylprednisone has not been used in clini-
cal practice in the last decade due to its side effects and the 
emergence of more advanced therapeutic modalities.
The treatment of patients with AS and low back pain for 
more than three months with an injection of 40 mg of triam-
cinolone acetate in the sacroiliac joint guided by computed to-
mography (CT) demonstrated, after six months of follow up, 
a decrease in pain intensity (assessed by the visual analogue 
scale, VAS), and in sacroiliac pain (assessed by MRI) with evi-
dence of a 72% increased response (NNT: 1). There was also a 
signifi cant reduction of 31% in the use of NSAIDs and in Men-
nell’s sign (NNT: 3)20,21(B).
Recommendation 5
An intra-articular injection with triamcinolone acetate in the 
sacroiliac joint may provide short- and medium-term benefi ts, 
and it is a therapeutic option for cases that are non-responsive 
to NSAIDs and exhibiting isolated sacroiliac pain. There is no 
evidence that allows for the evaluation of low doses of predni-
sone (or equivalent corticosteroid) in ankylosing spondylitis.
6. In which situations should continuous NSAID 
use be recommended for patients with ankylosing 
spondylitis?
The comparison of the use of 20 mg/day piroxicam, 15 mg/day 
meloxicam, or 22.5 mg/day meloxicam in patients with AS for 
52 weeks showed a reduction in pain intensity in 27%, 28%, 
and 27% of patients, respectively. The increase in percentage 
response (Ankylosing Spondylitis Functional Index, ASFI) was 
similar after 6 weeks and 12 months of follow up after treatment 
with piroxicam, 15 mg meloxicam, and 22.5 mg meloxicam, be-
ing 20%, 33%, and 26%, respectively. A small percentage (16%; 
NNT: 6) of patients using 22.5 mg meloxicam had to discontinue 
treatment for 12 months compared with all other treatments. In 
52 weeks, there were signs of increased gastrointestinal adverse 
events of 19%, 7%, and 5% after treatment with piroxicam, 15 mg 
meloxicam, and 22.5 mg meloxicam, respectively22(A).
Patients with AS and pain between 40 mm and 100 mm 
(VAS), treated with etoricoxib at 90 mg/day, etoricoxib at 120 mg/
day, or naproxen at 500 mg 2x/day showed signifi cant improve-
ment in back pain (100 mm, VAS) and disease activity according 
to the patient global assessment (100 mm, VAS) and functional 
assessment (BASFI) after six weeks of follow-up. Comparing 
medications, etoricoxib had results superior to naproxen, while 
the different doses of etoricoxib had similar results. There was 
an increase in the proportion of patients achieving the criteria 
for partial remission with 90 mg etoricoxib (NNT: 9), 120 mg 
etoricoxib (NNT: 7), and naproxen (NNT: 16). There was no differ-
ence between adverse events; the most common adverse events 
were as follows: headache; diarrhoea; heartburn; respiratory in-
fection; and gastrointestinal and cardiovascular events23(A).
In patients requiring daily NSAID treatment and exhibiting 
a pain intensity greater than 50 mm (VAS), a comparison of 
celecoxib at 200 mg/day, celecoxib at 400 mg/day, or naproxen 
at 500 mg 2x/day showed, at 12 weeks, that the three treatment 
regimens produced improvements and benefi ts with regard 
to pain intensity, disease activity (patient global assessment, 
VAS), functional improvement (BASFI), and adverse events. The 
regimen with the lowest effect was 200 mg celecoxib.
The most common adverse event was gastrointestinal disor-
ders, the most common of which was dyspepsia. With naprox-
en, there were severe events (ulcers and haemorrhage)24(A). A 
comparison of celecoxib at 200 mg or 400 mg with diclofenac 
at 72 mg 2x/day showed a 13% (NNH:8) increase in gastrointes-
tinal adverse events with diclofenac25(A). 
As per the analgesic action in AS patients, the NNT in six 
weeks of follow-up of 90 mg etoricoxib, 120 mg etoricoxib, and 
1 g naproxen, relative to back pain improvement (≥ 30%), was 2, 
2, and 3, respectively; relative to an improvement ≥ 30% in the 
BASDAI score, the NNT was 2, 2, and 3, respectively26(A).  
Using NSAIDs (celecoxib at 100 mg or 200 mg 2x/day) con-
tinuously or on demand over two years in AS patients can lead 
to benefi ts related to the signs and symptoms and radiological 
progression of the lesion (Stoke Ankylosing Spondylitis Spine 
Score) or damage related to adverse events. The signs and 
symptoms after 24 months of follow up were similar between 
the two regimens; however, the radiological progression was 
three times higher in the on-demand regimen than in the con-
tinuous regimen. Although there were more adverse events in 
the continuous regimen, the difference was not signifi cant. The 
most common adverse events were hypertension, abdominal 
pain, and dyspepsia27(A).
Recommendation 6
The continuous use of NSAIDs is more effective then on-de-
mand use. In patients with moderate to severe pain, the pre-
scription of COX-2 inhibitors is a long-term treatment option.
7. What is the evidence for the use of conventional 
drugs (methotrexate and sulfasalazine, among 
others) in patients with ankylosing spondylitis?
Methotrexate
There is evidence that the use of methotrexate at 10 mg/week 
for 24 weeks in patients with AS produces no difference in dis-
ease activity (as measured by BASDAI) and mobility (as mea-
sured by BASMI) compared to patients without methotrexate 
treatment28(B).
A response (compound index) to treatment of AS patients 
with methotrexate at 7.5 mg/week for 24 weeks is considered 
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when a result ≥ 20% is obtained in at least fi ve of the following 
scales: a) intensity of morning rigidity (VAS); b) physical well-
being (VAS); c) disease activity (BASDAI); d) function (BASFI); e) 
function (Health Assessment Questionnaire for Spondyloar-
thropathies, HAQ-S); f) disease activity (Physician’s global as-
sessment, VAS); and g) disease activity (How do you describe 
the current level of disease activity?). When comparing pa-
tients with receiving methotrexate or not, we observed a 42% 
increase (NNT: 2) in response (compound index) at 24 weeks 
and a 32% increase (NNT: 3) in response (BASDAI). Adverse 
events did not differ among patients who did or did not use 
methotrexate29(A).
Sulfasalazine
There was no difference between the beginning of treatment 
with sulfasalazine (2 to 3 g/day) and after 3-36 months of treat-
ment with regard to physical function, pain, spine mobility, pe-
ripheral arthritis, and patient global assessment. However, when 
comparing the outcomes of response among patients treated 
or not with sulpha, there was a signifi cant difference in favour 
of treatment. Regarding spine rigidity, sulfasalazine treatment 
reduced the score (VAS), although there was no difference in 
outcome regarding morning rigidity. There was an increase of 
0.47 in the risk of loss of adherence to treatment due to adverse 
events in patients treated with sulpha (relative risk reduction), 
with reports of serious adverse reactions (pruritic erythematous 
rash, with nausea, anorexia, and insomnia)30(A). 
In patients with axial SpA, remission (ASAS criteria and 
MRI) at 48 weeks was greater in patients treated with etaner-
cept (33%) compared with sulphasalazine (11%). However, after 
a year of follow up, there was no difference in the response be-
tween the two treatments31(B). 
Lefl unomide
In AS patients, the number of responders according to the 
ASAS20 criteria with the use of lefl unomide (27%) was similar 
to patients not undergoing treatment (20%). After 24 months of 
treatment, there was no signifi cant difference in disease activity 
(BASG), the index of disease activity (BASDAI), the functional in-
dex (BASFI), pain, mobility (BASMI), or joint oedema. There was a 
20% increase (NNT: 5) in the risk of adverse events: gastrointes-
tinal disorders; respiratory infections; dermatitis and pruritus; 
fatigue; venous thrombosis; and elevated hepatic enzymes32(A). 
Recommendation 7
Methotrexate and sulfasalazine represent therapeutic options 
for ankylosing spondylitis.
8. What are the indications for the use of biological 
agents that block tumour necrosis factor (anti-TNF) 
in ankylosing spondylitis?
Infl iximab
The treatment of patients with active or severe AS (BASDAI ≥ 4 
and back pain ≥ 4 mm, VAS) by means of an intravenous infu-
sion of infl iximab (5 mg/kg) on weeks 0, 2, and 6 can produce 
benefi ts related to a reduction in disease activity by 50% as 
measured by the criteria of disease activity (BASDAI), func-
tional index (BASFI), and mobility (BASMI).
Infl iximab is effective with regard to all criteria: a 44% 
(NNT: 2) increase in the percentage of patients with an im-
proved BASDAI (50% improvement) at 12 weeks, with a 38% 
improvement in the score relative to the previous week at 
the start of the treatment; a 27% (NNT:4) and 17% (NNT:6) 
reduction in the percentage of arthritis and enthesitis after 
12 weeks, respectively; a 27% (NNT:3) reduction in the use of 
NSAIDs (50%); and a 28% (NNT:4) reduction in the number of 
patients using NSAIDs during the period. The most frequent 
adverse events were respiratory infection, ganglionic tubercu-
losis, fever, and leukopenia33(A).
Maintenance of treatment with infl iximab (5 mg/kg every 
6 weeks) after the initial phase (weeks 0, 2, and 6) and after 54 
weeks showed that 47% of the patients (NNT: 2) had a reduced 
BASDAI (50% reduction). Medication use was reduced by 70%, 
with a 33.3% reduction in the indices of peripheral arthritis 
and enthesitis (NNT: 3) and a 31% reduction in the number of 
hospitalisations (NNT: 3)34,35(B).
Over two years, 58% of patients achieved at least 50% 
reduction in the BASDAI score, which is similar to the re-
sponse level after a year. Of the treated patients, 94% and 85% 
reached at least a 20% response on BASDAI in weeks 54 and 
102, respectively. Changes in the BASFI and BASMI score were 
signifi cant compared with the beginning of the treatment, 
and they were similar between years one and two of follow 
up36(A). During the second year of follow up, 90% of patients 
reported adverse events, with the most frequent being respi-
ratory infection, rhinitis, herpes, osteoporosis, syncope, pan-
creatitis, and metrorrhagia37(B). After three years (156 weeks) 
of follow up, response to treatment measures by the ASAS40 
was 50%38(B). After fi ve years of follow-up, the ASAS20 and 
ASAS40 responses were 84% and 63%, respectively39(B).
At the end of eight years of follow up, a state of lower dis-
ease activity (BASDAI < 3) was achieved in 63.6% of patients, 
and this result was similar to that obtained at three months of 
follow-up. Furthermore, 71.4% remained with BASDAI values 
< 3. The ASAS20 response was maintained at 84.8%, and BAS-
DAI50 was present in 57.6% of the cases. The adverse events 
were tuberculosis, allergic granulomatosis, pancreatitis, and 
an overall decrease in general health. There was a reduction 
in enthesitis by 30.3% (NNT: 3), in peripheral arthritis in 21.2% 
(NNT: 5), and uveitis in 36% (NNT: 3)40(B).
The ASAS20 criteria as a measure of response to treat-
ment of AS patients is composed of at least a 20% improve-
ment after treatment, with absolute improvement of at least 
one unit (scale 0 to 10) in at least three of the following ar-
eas without deterioration of the initial condition: patient 
global assessment; back pain; function (BASFI); and morn-
ing rigidity (questions fi ve and six of BASDAI). AS patients 
with BASDAI ≥ 4 and back pain ≥ 4 mm (VAS) treated with 
5 mg/kg infl iximab on weeks 0, 2, 6, 12, and 18 show an in-
crease of 42% (NNT: 2) in the ASAS20 response and of 21.1% 
(NNT: 5) in partial ASAS response after 24 weeks of follow 
up. The BASDAI response increases in 40.3% (NNT: 2) and the 
BASFI response in 34.2% (NNT: 3) of patients. Serious adverse 
events occur such as dizziness, cholecystitis, arthritis, leuko-
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cytosis, pneumonia, hemiparesis, low back pain, fever, and 
ganglioneuroma36(A).
In patients with AS and a BASDAI score ≥ 4, treatment with 
infl iximab at 3 mg/kg on weeks 0, 2, and 6 led to, at 12 weeks 
of follow up, increases in the percentage of patients who 
reach ASAS20 by 23.2% (NNT: 4) and those who reach ASAS40 
by 37.9% (NNT: 3). At up to one year of follow up, the increased 
dose of 5 mg/kg maintained the clinical response. The most 
common adverse events were nasopharyngitis, respiratory 
infection, itching, nausea, dizziness, headache, and fever41(A). 
Etanercept
Patients with active AS, defi ned by infl ammatory back pain, 
morning rigidity for at least 45 minutes and moderate dis-
ease activity, who underwent treatment with etanercept at 
25 mg SC 2x/week for four months, increased the treatment 
response by 50% (NNT: 2), defi ned as ≥ 20% improvement in 
three of fi ve measures of disease activity (ASAS, BASFI, pa-
tient global assessment, and joint swelling). Adverse events 
were mild infection, diarrhoea, tinnitus, and headache42(A).
In patients with active AS (BASDAI ≥ 4 and with back pain 
≥ 4 mm, VAS), treatment with etanercept at 25 mg SC 2x/week 
for six months had the following benefi ts: a 51% increase in 
BASDAI50 score (NNT: 2); a 53.6% increase in ASAS20 score 
(NNT: 2); and a 55% increase in the discontinuation of the 
use of NSAIDs (NNT: 2). In the three-month follow-up, 75% 
of the patients showed reoccurrence, and the most common 
adverse event was respiratory infection43(A). 
The treatment of patients with active AS (a score of 30 mm 
for morning rigidity measured by VAS and a score of 30 mm for 
two of three parameters – patient global assessment, low back 
pain measured by VAS, and BASFI score) with etanercept at 25 
mg SC 2x/week for 24 weeks resulted in an increase of 31% 
(NNT: 3) in ASAS20 at 12 weeks, an increase of 35% (NNT: 3) in 
ASAS20 at 24 weeks, and an increase in the BASDAI score and in 
mobility. Regarding adverse events, the most common were as 
follows: lymphadenopathy; cellulitis; respiratory infection; ul-
cerative colitis; intestinal obstruction; and bone fractures44(A). 
The proportions of patients who, after 192 weeks of treatment, 
achieved ASAS20 and ASAS40 responses were 81% and 69%, re-
spectively, with increases of 33% and 39% compared with the 
scores after two weeks of treatment45(B). 
Considering AS activity with an intensity ≥ 30 mm (VAS) 
measured in four domains [spinal infl ammation (score), low 
back pain, global disease activity assessment, and physical 
function], the prescription of etanercept (25 mg, 2x/week) for 
12 weeks resulted in a 37% increase (NNT: 3) in the ASAS20 
response, a 50% increase in the ASAS50 response, a 43% im-
provement in spinal infl ammation and low back pain, a 37% 
reduction in the patient global assessment, a 35% improve-
ment in the functional index (BASFI), and a 62% improvement 
in the disease activity index (BASDAI). The most common ad-
verse events were as follows: allergic reaction or bleeding at 
the site of injection; headaches; nausea; asthenia; dizziness; 
diarrhoea; rash; abdominal pain; and paresthesia46(A).
AS patients showing one of the criteria that defi nes severe 
spinal ankylosis (i.e., two intervertebral adjacent bridges and/
or lumbar spine fusion; three intervertebral adjacent bridges 
and/or thoracic spine fusion; or two intervertebral adjacent 
bridges and/or cervical spine fusion) can be treated with etan-
ercept at 50 mg/week for 12 weeks. This treatment led to im-
provement in the following parameters: a 34% increase (NNT: 
3) in the percentage of patients who achieve ASAS20; a 23% 
increase (NNT: 5) in patients who achieve BASDAI50; a 25% 
increase (NNT: 4) in the number of patients with improve-
ments through Minimum Clinically Important Improvement 
(MCII); and improvement of parameters of pulmonary func-
tion (vital capacity, VC), forced VC, and the FEV1/VC ratio. The 
most common adverse events were infusion reactions and 
neutropenia47(A).
AS with infl ammatory activity (BASDAI ≥ 4 and back pain ≥ 
4) maintained for more than 12 weeks that is non-responsive 
to treatment of less than two NSAIDs for at least three months 
can be treated with etanercept at 50 or 100 mg/week for 12 
weeks with the following results: there was no difference be-
tween the two treatments with respect to ASA20, ASAS40, par-
tial remission, or BASDAI. Adverse events in both treatment 
regimens did not differ, the main such events being infection, 
gastrointestinal disorders, and infusion reactions48(A). 
Adalimumab
The treatment of AS patients non-responsive to NSAIDs with 
40 mg adalimumab every other week for 24 weeks reduces 
pain [measured by total back pain scores (VAS), night pain 
(VAS), Medical Outcomes Study Short Form-36 Health Sur-
vey (SF-36)], improvement of fatigue and of disease activity 
(measured by BASDAI), and improvement in morning rigidity 
(BASFI)49(B).
AS patients treated with 40 mg adalimumab every other 
week for 24 weeks showed improvement in activities related 
to the disease (BASDAI), function (BASFI), and quality of life 
[measured by AS Quality of Life Questionnaire (ASQoL)]. There 
was a 27.2% increase (NNT: 4) in the Minimum Clinically Im-
portant Difference (MCID) score. The responses/improve-
ments measured by the ASA20 and ASAS40 scores were 64.5% 
and 50.6%, respectively, and these were maintained for two 
years of treatment. The follow up of patients for three and 
fi ve years of treatment showed the stability of the response 
measured by various scores, including SF-3650-52(A).
Golimumab
AS patients with a BASDAI score ≥ 4, a back pain score ≥ 4 
(VAS), and an inadequate response to previous use of NSAIDs 
or drugs that alter the disease course, when treated with go-
limumab at 50 mg or 100 mg every four weeks for 24 weeks, 
showed the following results: 37.6% and 38.2% increases in the 
ASAS20 responses for the 50 mg and 100 mg doses, respective-
ly; 28.1% and 38.9% increases in the ASAS40 responses for the 
50 mg and 100 mg doses, respectively; and a 36.1% increase 
in the percentage of patients who achieve a BASDAI50 score 
(NNT: 3). Up to the 24th week, the proportion of patients who 
experienced at least one adverse event was 79.9%, regardless 
of dose, but with an increase in patients who did not use active 
drugs. The adverse events included the following: nasophar-
yngitis; respiratory infections; fatigue; headache; diarrhoea; 
erythema at the injection site; and increased liver enzymes. 
The proportion of patients with a serious adverse event was 
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3.6% with the 50 mg dose and 6.4% with the 100 mg dose. The 
adverse events included the following: myocardial infarction; 
fatigue; depression; hypertension; chest pain; blepharitis; nau-
sea; vomiting; hepatitis; infl uenza-like symptoms; pain in the 
extremities; and weight gain53(A). There were signs of benefi ts 
with respect to sleep quality [measured by the Jenkins Sleep 
Evaluation Questionnaire (JSEQ)]54(A). The follow up of these 
patients for two years showed good maintenance of this good 
response according to the different scores.55
Recommendation 8
Patients with active and severe AS, clinically defi ned as BAS-
DAI ≥ 4 and back pain ≥ 4 mm (VAS), and with no response for 
three months with NSAIDs and/or drugs that can alter the 
disease course can be treated as follows: with infl iximab at 
3-5 mg/kg every six to eight weeks for up to eight years of 
follow up; with etanercept at 50 mg per week, for up to four 
years of follow up; with adalimumab at 40 mg every other 
week for up to fi ve years of follow up; or with golimumab at 
50 mg every four weeks, for up to two years.
9. Is there a difference in effi cacy among anti-TNF 
drugs in patients with ankylosing spondylitis?
The main results of individual effi cacy of infl iximab, etaner-
cept, adalimumab and golimumab in BASDAI, ASAS, discon-
tinuation of NSAIDs, hospitalisation, arthritis, and enthesitis 
are described below.
Infl iximab
Infl iximab is effective with the following criteria: a 44% in-
crease (NNT: 2) in the percentage of patients with an improved 
BASDAI50 at 12 weeks, with a 38% improvement in the score 
compared to the week prior to treatment; a 27% (NNT: 4) and a 
17% (NNT: 6) reduction in the percentage of patients experienc-
ing arthritis and enthesitis, respectively, after 12 weeks; a 37% 
reduction (NNT: 3) in the use of NSAIDs (50%); and a 28% in-
crease (NNT: 4) in the number of patients not needing NSAIDs 
in that period33(A).
After 54 weeks, 47% of the patients (NNT: 2) had a 50% re-
duction in BASDAI; the use of other medications also decreased 
by 70%. There was a 33.3% (NNT: 3) reduction in the prevalence 
of peripheral arthritis and enthesitis and a 31% reduction in 
the number of hospitalisations (NNT:3)34,35(B).
In the two-year follow-up, 58% of the patients reached at 
least a 50% reduction in BASDAI, which is a level similar to 
the one-year response. Of the patients treated, 94% and 85% 
achieved at least 20% BASDAI response at weeks 54 and 102, 
respectively37(B).
The effi cacy measured by ASAS40 is 50%37(B). After fi ve years 
of follow up, the ASAS20 and ASAS40 responses were 84% and 
63%, respectively39(B). At the end of the eight years of follow 
up, a lower activity state of disease (BASDAI < 3) was present 
in 63.6% of patients – results similar to those obtained in three 
months of follow up. Furthermore, 71.4% of patients remained 
with BASDAI values < 3; the ASAS20 response is maintained at 
84.4%, and BASDAI50 is present in 57.56% of all cases40(B).
After 24 weeks of follow up, there was a 42% increase (NNT: 
2) in ASAS20 response and 21.1% increase (NNT: 5) in partial 
ASAS response. The BASDAI response increases in 40.3% (NNT: 
2) and the BASFI response in 34.2% (NNT: 3)40(A). In 12 weeks of 
follow up, there was an increase of 23.2% (NNT: 4) in the per-
centage of patients who achieved ASAS20 and of 37.9% (NNT: 3) 
in patients who achieved ASAS4040(A).
Etanercept
Etanercept use has benefi ts for treated patients; it increased 
the BASDAI50 response by 51% (NNT: 2), the ASAS20 score by 
53.6% (NNT: 2), and discontinuation of NSAID use by 55% (NNT: 
2)40(A). Furthermore, it resulted in a 31% increase (NNT: 3) in 
ASAS20 after 12 weeks, a 35% increase (NNT: 3) in ASAS20 after 
24 weeks, and improvements in BASDAI score and mobility44(A).
The proportions of patients who reach ASAS20 and ASAS40 
responses after 192 weeks of treatment are 81% and 69%, re-
spectively, with increases of 33% and 39% compared with the 
score two weeks prior to treatment45(B).
The use of etanercept resulted in a 37% increase (NNT: 3) in 
ASAS20 response, a 50% increase in the ASAS50 response, a 43% 
improvement in spine infl ammation and low back pain, a 37% 
reduction in the overall assessment of the patients, and 35% 
and 62% improvements in BASFI and BASDAI, respectively46(A).
Adalimumab
The responses/improvements measured by the ASAS20 and 
ASAS40 score were 64.5% and 50.6%, respectively, and were 
maintained over two years of treatment50,51(A).
Golimumab
At 24 weeks, Golimumab showed the following results: in-
creases of 37.6% and 38.2% in ASAS20 for the 50 mg and 
100 mg doses, respectively; increases of 28.1% and 38.9% in 
ASAS40 with the 50 mg and 100 mg doses, respectively; and 
a 36.1% increase (NNT: 3) in the percentage of patients who 
achieved BASDAI5053,54(A).
Synthesis of the results by outcome
Tables 1, 2, and 3 show the synthesis of the BASDAI and ASAS 
outcomes, and reduction of NSAID use, respectively.
Arthritis and enthesitis
Infl iximab
A reduction of 27% (NNT: 4) and of 17% (NNT: 6) at 12 weeks.
A reduction of 33% (NNT: 3) at 54 weeks.
Hospitalisation 
Infl iximab
A reduction of 31% (NNT: 3) at 54 weeks.
The common outcome among the medications allows for 
indirect comparison by calculation of NNT for the main out-
comes: BASDAI 20 and 50, ASAS 20 and 40, and a reduction in 
NSAID use (50%) (Table 4).
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Recommendation 9
The anti-TNF biological agents (infl iximab, etanercept, adali-
mumab, and golimumab) showed benefi ts in the treatment 
of AS patients with regard to the BASDAI and ASAS criteria 
and NSAID use. None of the drugs was more effective than 
the others.
10. Is there a difference in the safety among 
the anti-TNF drugs in patients with ankylosing 
spondylitis? 
There is heterogeneous information with regard to adverse 
events among the four medications being used, likely due 
to factors such as follow-up time, the number of consistent 
studies available, the multiplicity of events that occur, and 
partial information retrieved. Nevertheless, several adverse 
events are common to all forms of treatment.
Infl iximab
The most common adverse event was respiratory infection, 
which can lead to ganglionar tuberculosis, pulmonary gran-
ulomatosis, or leukopenia. Discontinuity of treatment due to 
severe adverse events occured in 12% of patients33(A).
A high proportion of patients (82.2%) showed more than 
one adverse event. The majority of adverse events were 
moderate; however, 3.5% of patients showed serious adverse 
events (dizziness, cholecystitis, arthritis, leukocytosis, pneu-
monia, hemiparesis, low back pain, fever, and ganglioneu-
roma), and 2.7% of patients discontinued treatment. Other 
adverse events were pharyngitis, rhinitis, a transient eleva-
tion of liver enzymes, and nausea36(A).
Severe adverse events occurred at a rate of 12%, and the 
discontinuation rate was 6%. During the second year of fol-
low up, 90% of patients reported adverse events, and the most 
frequent were the following: respiratory infection, rhinitis, 
herpes, myalgia, pancreatitis, and infusion reactions37(B).
Adverse events occurred 90.8% of the time; most were 
moderate, but 18.4% were severe, 9.2% required hospitali-
sation, and 2.6% led to discontinuation of treatment. The 
most common adverse events were nasopharyngitis, respi-
ratory infection, itching, nausea, dizziness, headache, and 
fever41(A).
Of the patients who discontinued treatment, 55% did 
so due to the adverse events, which most frequently were 
increased liver enzymes, infusion reaction, and a loss of 
effi cacy. Other adverse events were tuberculosis, allergic 
granulomatosis, pancreatitis, and a worsening of the general 
condition. There has been shown a 30.3% reduction (NNT: 3) 
in enthesitis, 21.2% (NNT: 5) in peripheral arthritis, and 36% 
(NNT: 3) in anterior uveitis40(B).
Etanercept
The most common adverse events were mild infections, in-
jection site reactions, diarrhoea, tinnitus, orbicular oculi fas-
ciculation, headache and respiratory infections, nausea, as-
thenia, dizziness, abdominal pain, and paresthesias42,43,46(A).
There may be a 5% discontinuity in the treatment with 
etanercept due to adverse events, with the most common 
being the following: lymphadenopathy; cellulitis; respiratory 
Table 1 – Increases in fi nal outcome (in %) of BASDAI 
(20, 50, and < 3) at various follow-up times (12, 24, 54, 
and 102 weeks and 8 years) by medication (infl iximab, 
etanercept, adalimumab, golimumab) compared with 
the placebo.
Medication BASDAI 20 BASDAI 50 BASDAI < 3
Time of 
follow up
Time of 
follow up
Time of 
follow up
12 
wks.
54 
wks.
102 
wks.
12 
wks.
24 
wks.
54 
wks.
8 years
Infl iximab 94% 85% 44% 40.3% 58% 63.6%
Etanercept 62% 51% 23%
Adalimumab
Golimumab 36.1%
Table 2 – Increases in fi nal outcome (in %) for ASAS 
(20 and 40) at different follow-up times (12 and 24 
weeks and > 2 years) by medication (infl iximab, 
etanercept, adalimumab, golimumab) compared with 
the placebo.
Medication ASAS 20 ASAS 40
Time of follow up Time of follow up
12 
wks.
24 
wks.
> 2 
yrs.
12 
wks.
24 
wks.
> 2 
yrs.
Infl iximab 23.2% 42% 84.8% 37.9% 63%
Etanercept 37% 35% 33% 39%
Adalimumab 64.5% 50.6%
Golimumab 37.6% 28.1%
Table 3 – Increases in fi nal outcome (in %) in the 
reduction of NSAID use (50%) at various follow-up 
times (8, 12, and 54 weeks) by medication (infl iximab, 
etanercept) compared with the placebo.
Medication Reduction in NSAID 
Time of follow up
8 wks. 12 wks. 54 wks.
Infl iximab 37% 70%
Etanercept 55%
Table 4 – The number needed to treat (NNT) in the 
maximum follow-up time, by medication (infl iximab, 
etanercept) compared with the placebo.
Medication Outcome
BASDAI (NNT) ASAS (NNT) Reduction of 
50% in the 
use of NSAIDs 
(NNT)
20 50 20 40
Infl iximab 1 2 1 2 1
Etanercept 2 5 3 3 2
Adalimumab 2 2
Golimumab 3 3 3
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infection; ulcerative colitis; intestinal obstruction; and bone 
fractures44(A). 
Severe adverse events (lung cancer and neutropenia, 5%) 
also led to discontinuation of treatment. The most common 
adverse events (62% of cases) were infusion reaction and 
neutropenia47(A).
Fifty percent of patients experienced adverse events, and 
5% of these were severe (diarrhoea with abdominal pain and 
distension). The main adverse events were infections, gastro-
intestinal disorders, and infusion reactions48(A).
Adalimumab
During two years of adalimumab use, adverse events were 
moderate and the most common (5%) were nasopharyngitis, 
respiratory infection and headache, and Crohn’s disease; 10% 
were severe adverse events, 4.5% led to discontinuation of the 
medication, 1.3% were neoplasias, and 3.9% were uveitis50(A).
Golimumab
Up to the 24th week, the proportion of patients who experi-
enced at least one adverse event was 79.9%, with no difference 
with respect to dosing but with an increase in patients not 
using the active drug. These adverse events included the fol-
lowing: nasopharyngitis; respiratory infections; fatigue; head-
ache; diarrhoea; erythema at the injection site; increased liver 
enzymes; and at least one infection (48.6%). The proportion of 
patients with one severe adverse event was 3.6% with 50 mg 
and 6.4% with 100 mg; among them were the following: myo-
cardial infarction; fatigue; depression; hypertension; chest 
pain; blepharitis; nausea; vomiting; hepatitis; infl uenza-like 
symptoms; extremity pain; and weight gain. Due to these ef-
fects, 2.9% of patients discontinued treatment53(A).
Recommendation 10
The moderate and severe adverse events and treatment dis-
continuation show similar indices and types in all four treat-
ment regimens (infl iximab, etanercept, adalimumab, and go-
limumab). No drug is safer than the others.
11. Is the use of anti-TNF treatment capable of 
reducing structural damage in patients with 
ankylosing spondylitis?
Infl iximab
The treatment of AS patients with infl iximab at 5 mg/kg re-
duced the number of bone lesions (by MRI) in 30 weeks of fol-
low up. This result was superior when combined with metho-
trexate compared with treatment with methotrexate alone. A 
signifi cant increase in bone mineral density occurred in pa-
tients treated with infl iximab, especially in the femur, pelvis, 
and spine56(A). 
AS patients treated with infl iximab at 5 mg/kg every six 
weeks for three years can be evaluated using the modifi ed 
Stokes Ankylosing Spondylitis Spinal Score (mSASSS), consid-
ering as a lesion the presence of at least one syndesmophytes 
(mSASSS > 2) and, by radiological progression, defi ned as the 
change from 0 to 1 for syndesmophytes or ankylosis (mSASSS 
> 2). In this period, there was an increase in mSASSS score 
and in the number of patients (increase in 11.3% – NNH: 8) 
with radiological lesions, with the development of new le-
sions being common in the fi rst two years of treatment, slow-
ing in the following period57(B). 
The use of infl iximab at 5 mg/kg for 96 weeks in AS patients 
led to an mSASSS score increase, although 34% of patients 
showed a decrease of one or more points. Furthermore, some 
patients show a decrease of two or more (19.9%), three or more 
(14.7%), and four or more (10.9%)58 points in the score(B).
Etanercept
The changes in radiographic score of bone lesions (mSASSS) 
in the cervical and lumbar spine after 96 months of treatment 
with etanercept were similar to the ones observed in patients 
with no treatment, with a worsening in the scores compared 
with the beginning of treatment59(B). 
Recommendation 11
The use of anti-TNF drugs (infl iximab and etanercept) pro-
duces no reduction in the structural damage in patients with 
ankylosing spondylitis.
12. Is there evidence for the effi cacy and safety of 
anti-TNF drugs in extra-articular manifestations 
in patients with ankylosing spondylitis?
Uveitis
Among the AS patients treated with infl iximab, the incidence 
of anterior uveitis was 3.4 per 100 patients/year compared 
with patients treated with etanercept, with an incidence of 7.9 
per 100 patients/year. In non-treated patients, the incidence 
of anterior uveitis was 15.6 per 100 patients/year, a signifi cant 
difference compared with those receiving anti-TNF drugs60(B).
The use of 40 mg adalimumab every other week for 12 
weeks in AS patients reduced the incidence of anterior uve-
itis by 51% (NNT: 2), reduced in 58% of patients (NNT: 2) the 
incidence of anterior uveitis in patients with a history of uve-
itis, in 68% (NNT: 2) of patients with a recent history, in 50% 
(NNT: 2) of patients with symptomatic anterior uveitis, in 45% 
(NNT: 2) of patients with chronic uveitis, and reduces the oc-
currence of uveitis in 58% of patients (NNT: 2)61(B).
Infl ammatory bowel disease
In AS patients, it is estimated that infl ammatory bowel dis-
eases (Crohn’s disease and ulcerative colitis) affects 1.3 per 
100 patients/year. The treatment of these patients with anti-
TNF for a period of 14 to 156 weeks has distinct results de-
pending on the drug used: infl iximab 0.2 patients/year, etan-
ercept 2.2 patients/year, and adalimumab 2.3 patients/year, 
with this difference being favourable and signifi cant for the 
use of infl iximab. Infl iximab treatment (0.04) reduced the risk 
of infl ammatory bowel disease in 42% (NNT: 2) of patients 
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compared with etanercept and in 12% (NNT: 8) of patients 
compared with adalimumab62(B).
Psoriasis
The use of adalimumab, etanercept, and infl iximab in AS pa-
tients may be associated with the development of psoriasis 
[psoriasis vulgaris (psoriasis plaque) or palmoplantar pus-
tular] after an average of four months. However, in approxi-
mately 40% of patients with psoriasis, the anti-TNF use re-
solved the lesions63(C).
Osteoporosis
The use of anti-TNF agents for two years in AS patients can 
result in increased bone mineral density in the spine and fe-
mur, regardless of the presence of lumbar syndesmophytes. 
The changes in bone density in the lumbar spine correlated, 
in two years of follow up, with changes in BASDAI and BASFI 
scores. There were no differences between the results ob-
tained with infl iximab and etanercept64(C).
Recommendation 12
With regard to the extra-articular manifestations, anti-TNF 
drugs reduce the incidence of anterior uveitis in patients with 
ankylosing spondylitis, can reduce the incidence of infl amma-
tory bowel disease (especially infl iximab), show controversial 
results as to benefi t or damage with regard to the induction 
of psoriasis, and cause an increase in bone mineral density 
aligned with the clinical response in ankylosing spondylitis.
13. What is the evidence that supports the switch 
of anti-TNF agents in patients with ankylosing 
spondylitis?
Of the AS patients who discontinued infl iximab treatment (5 
mg/kg every six to eight weeks, during the last two years) due 
to clinical failure (absence of BASDAI score reduction), 70% 
responded to a switch to etanercept, with an average reduc-
tion in BASDAI of 7.1 (± 3.6) to 4.1 (± 7.3) in ten months of 
follow-up65(C).
AS patients treated with 5 mg/kg of infl iximab every eight 
weeks with a failure to maintain a clinical response of 20% ac-
cording to the ASAS20 can be treated with 50 mg of etanercept 
for 24 to 54 weeks, without showing severe adverse events (in-
fusion reaction, dizziness, headache) but with the following 
benefi ts: 78% ASAS20 response, 52% ASAS50 response, and 
39% ASAS70 response, in 24 weeks; and 74% ASAS20 response, 
61% ASAS50 response, and 39% ASAS70 response, in 54 weeks; 
changes in BASDAI score from 6.9 (± 1.3) to 3.1 (± 3.1) in the 
24th week and to 2.9 (± 1.7) on the 54th week66(B). 
When defi ning the response to anti-TNF treatment in AS 
patients as a 50% response in the BASDAI score, a clinical re-
sponse was obtained in 75% of patients who switched form 
infl iximab to etanercept and in 57.1% of those who switched 
from etanercept to adalimumab. The patients who switched 
anti-TNF agents due to adverse events or inadequate effi cacy 
presented with a similar clinical response (70% and 61.5%, 
respectively). The patients who switched from infl iximab to 
etanercept showed a response after three months of 83.3% 
(NNT: 1)67(B).
The use of anti-TNF medication (infl iximab, etanercept, 
adalimumab) in the treatment of AS patients demonstrated 
after 12 weeks an 88% clinical response (measured by BASDAI 
and BASFI scores). Of the patients who did not respond, or 
of those who exhibited severe adverse reactions during treat-
ment despite having a good response, 13% switched anti-TNF 
agents; of those, 93% showed a clinical response after the 
switch68(C).
The patients with severe AS in treatment with infl iximab, 
etanercept, or adalimumab may need to switch anti-TNF 
agents (17% of cases) due to ineffi ciency (67%) or adverse 
events (28%). Of these patients, 67% and 86% maintained a 
response (measured by the reduction of 50% in BASDAI) at 6 
to 12 months, respectively. The average value of BASDAI (IQR) 
before the switch was 6.92, and after the switch, at 3, 6, and 12 
months, it was 3.98, 370, and 2.92, respectively69(B). 
Of the 38% of AS patients who did not achieve a clinical 
response after treatment with anti-TNF agents in three to 
four months, approximately 24% and 11%, respectively, re-
quired a second or third different anti-TNF agent. Of the pa-
tients treated with a second anti-TNF agent, 46% showed an 
adequate response. Of the patients requiring a third anti-TNF 
agent, 100% obtained a complete response70(B).
The patients who switched anti-TNF medication (16%) 
were treated with their fi rst medication (etanercept, infl ix-
imab, or adalimumab) for an average of 294 days and started 
the second anti-TNF agent 32 days, on average, after discon-
tinuing the fi rst medication. Etanercept was administered 
subcutaneously at a dose of 25 mg 2x/week or 50 mg 1x/
week. Infl iximab was prescribed intravenously on weeks 0, 2, 
and 6 and every six to eight weeks, with an average dose of 
4-5 mg/kg. Adalimumab was administered subcuteaneously 
at 40 mg every 15 days. After three months of the fi rst anti-
TNF switch, the clinical response as measured by BASDAI50, 
ASAS20 and ASAS40 was 25%, 47%, and 30%, respectively. Af-
ter three months of treatment with the second anti-TNF, the 
response as measured by BASDAI50, ASAS20, and ASAS40 was 
28%, 40%, and 30%, respectively. There was no difference in 
response between the fi rst and the second switch71(B).
The switch of anti-TNF agents due to insuffi cient response 
or adverse events increased in three months from 14% to 21% 
in the BASDAI 50 and ASAS 40, respectively, in the fi rst and 
second switch71(B). 
Recommendation 13
The switch of anti-TNF agent represents a therapeutic strate-
gic option when there is inadequate clinical response or ad-
verse events.
14. How long should anti-TNF drugs be used 
in the follow up of a patient with ankylosing 
spondylitis?
Treatment of AS for 102 weeks with infl iximab (5 mg/kg) re-
sulted in a 42% increase in the clinical response (ASAS20) ob-
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tained in the 24th week, and it was maintained in the second 
period. The clinical response measured by ASAS20 in the two 
weeks of treatment increased from 43% to 89%. Although in 
the 102nd week, 97.5% of patients showed adverse events. Dur-
ing the treatment, there was no difference in the occurrence 
of adverse events between the 24th and 102nd week. The in-
crease regarding patients not treated with infl iximab was 22% 
(NNH: 5). The most common adverse event was upper respira-
tory tract infection (48.7%)72(A).
In the following two years, 58% of the patients treated with 
infl iximab reached at least a 50% reduction in BASDAI, which 
was similar to the response level at year one. Of the treated 
patients, 94% and 85% reached at least 20% in the BASDAI re-
sponse in weeks 54 and 102, respectively. Adverse events in 
the second year (90% of patients) of treatment occurred in a 
proportion similar to the fi rst year37(B).
Partial remission, defi ned as a score ≤ 2 in each of the 
four ASAS domains (PatGA, NRS-P, BASFI, and BASDAI), was 
reached in 34.2% of the AS patients in fi ve years of treatment 
with infl iximab compared with 36.8% in three years of treat-
ment. After fi ve years of treatment, the effi cacy of infl iximab 
remained stable compared with the fi rst three years, with an 
average BASDAI score of 2.5 and 2.5, a BASFI of 3.0 and 2.9, a 
PatGA of 2.7 and 2.6, and a BASMI 2.8 and 2.6, respectively. 
There was no difference in adverse events between the two 
periods (94%)39(B).
After eight year of follow up, a state of low disease activity 
(BASDAI < 3) was achieved in 63.3% of patients treated with 
infl iximab, a result similar to that obtained in three months of 
follow-up. Furthermore, 71.4% of patients continued to have 
BASDAI values < 3. ASAS20 response was maintained in 84.8% 
of patients, and BASDAI50 was present in 57.6% of cases. Of 
the patients who discontinued treatment, 55% do so due to 
adverse events, of which, the most frequent were an increase 
in hepatic enzymes, infusion reaction, and loss of effi cacy40(B).
During fi ve years of follow up, there was a 50% increase 
(NNT: 2) in adherence to treatment with infl iximab due to the 
reduction of symptom reoccurrence73(B).
After 192 weeks of treatment with etanercept, 81% of 
patients reached an ASAS20 response, and 69% reached an 
ASAS40 response, with increases of 33% and 39%, respective-
ly, compared with the scores after two weeks of treatment. 
There was a 14.1% increase in adverse events and a 4.7% in-
crease in discontinuity compared with patients that were not 
treated with etanercept45(B).
The response/improvement with adalimumab treat-
ment, measured by ASAS20 and ASAS40 scores, was main-
tained during the three years of treatment and were 64.5% 
and 50.6%, respectively. Furthermore, the benefi ts measured 
by BASDAI, BASFI, and SF-36 score obtained in the 24th week 
were maintained up to the 156th week. Adverse events lead to 
discontinuity in 4.5% of cases in two years of treatment with 
adalimumab and 30% in three years50(A).
Recommendation 14
The long-term use of anti-TNF drugs in ankylosing spondy-
litis patients maintains the clinical response without an in-
crease in adverse events. Currently, it is estimated that its use 
should be for an indefi nite period of time.
15. Is there evidence for the use of biological agents 
with other mechanisms of action in ankylosing 
spondylitis?
Rituximab
The treatment of patients with active AS (BASDAI > 4) without the 
previous use of an anti-TNF with 1000 mg of rituximab during 24 
weeks produced a clinical response according to ASAS20, ASAS40, 
and BASDAI50 of 30%, 10%, and no response, respectively. In pa-
tients with a history of anti-TNF failure, the ASAS20, ASAS40, and 
BASDAI50 responses were 40%, 30%, and 50%, respectively74(B).
Tocilizumab
The patients with an AS diagnosis and Crohn’s disease who 
were not responsive to treatment with three biological agents 
(infl iximab, abatacept, and certolizumab) and were treated for 
11 months with tocilizumab (8 mg/kg every 15 weeks) showed 
a stable BASFI (6.0), improvement in BASDAI from 6.1 to 4.3, 
and a reduction of oedema and morning rigidity75(C). The AS 
patients who were unresponsive to infl iximab, etanercept, and 
adalimumab and were treated with tocilizumab 8 mg/kg every 
four weeks showed an improvement in BASDAI from 6.1 to 3.6 
and a reduction in ASDAS (Ankylosing Spondylitis Disease Ac-
tivity Score) from 5.8 to 1.6 after 26 weeks, although the MRI 
showed a persistence of infl ammatory signs76(C). The patients 
with AS treatment failure after fi ve years of treatment with anti-
TNF drugs (infl iximab, etanercept, and adalimumab) who were 
treated with tocilizumab 8 mg/kg showed a reduction in BASDAI 
from 3 to 0.9, BASFI from 6 to 1.5, and ASDAS 2.2 to 1.3 after four 
weeks (after 12 months, the reduction of ASDAS was 0.9)77(C). 
Abatacept
In patients with an AS diagnosis and active disease (BASDAI 
scores and low back pain ≥ 4), treatment with abatacept during 
24 weeks led to ASAS40 response in 13% of patients without a 
previous history of anti-TNF use and in 0% of non-responsive 
patients, regardless of previous treatment with at least two 
NSAIDs. The same was true for ASAS20, with indices of 27% and 
20%, respectively. There were no signs of response in the BAS-
DAI and ASDAS scores in the patients, neither for those without 
prior anti-TNF use nor for those without response78(B).
Recommendation 15
The use of rituximab and abatacept is not effective and does not 
justify its use in patients with ankylosing spondylitis. The avail-
able evidence for tocilizumab does not allow for it to be recom-
mended.
Appendix
Question 1
What are the clinical criteria for an individual to be consid-
ered affected by a spondyloarthritis?
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Spondylitis, Ankylosing OR Bechterew’s Disease OR Anky-
losing Spondyloarthritis OR Rheumatoid Spondylitis OR Ma-
rie-Struempell Disease AND specifi city [Title/Abstract]
Question 2
What is the role of MRI in the initial evaluation of axial spon-
dyloarthritis?
(Spondylitis, Ankylosing OR Bechterew’s Disease OR An-
kylosing Spondyloarthritis OR Rheumatoid Spondylitis OR 
Marie-Struempell Disease) AND Magnetic Resonance Imag-
ing AND (specifi city[Title/Abstract] OR (prognos*[Title/Ab-
stract] OR (fi rst[Title/Abstract] AND episode[Title/Abstract]) 
OR cohort[Title/Abstract]))
Question 3
When should HLA-B27 be requested in a patient with axial 
spondyloarthritis?
(Spondylitis, Ankylosing OR Bechterew’s Disease OR Anky-
losing Spondyloarthritis OR Rheumatoid Spondylitis OR Ma-
rie-Struempell Disease) AND HLA-B27 AND (specifi city [Title/
Abstract] OR (prognos*[Title/Abstract] OR (fi rst[Title/Abstract] 
AND episode[Title/Abstract]) OR cohort[Title/Abstract]))
Question 4
What is the evidence for the use of physical rehabilitation in 
patients with ankylosing spondylitis?
(Spondylitis, Ankylosing OR Bechterew’s Disease OR An-
kylosing Spondyloarthritis OR Rheumatoid Spondylitis OR 
Marie-Struempell Disease) AND HLA-B27 AND (specifi city 
[Title/Abstract] OR (prognos*[Title/Abstract] OR (fi rst [Title/
Abstract] AND episode [Title/Abstract]) OR cohort [Title/Ab-
stract])) 
Question 5
What is the evidence for the use of corticosteroids in patients 
with ankylosing spondylitis?
(Spondylitis, Ankylosing OR Bechterew’s Disease OR Anky-
losing Spondyloarthritis OR Rheumatoid Spondylitis OR Marie-
Struempell Disease) AND (Steroids OR Androstanes OR Andro-
stanols OR Androstenes OR Cardanolides OR Cardenolides OR 
Cardiac Glycosides OR Sterols OR Cyclosteroids OR Estranes OR 
Estrenes OR Gonanes OR Homosteroids OR Testolactone OR 
Hydroxysteroids OR Ketosteroids OR 17-Ketosteroids OR Nor-
steroids OR Norandrostanes OR Norpregnanes OR Pregnanes 
OR Pregnadienes OR Pregnanediol OR Pregnanediones OR Preg-
nanetriol OR Pregnanolone OR Pregnatrienes OR Pregnenes OR 
Tetrahydrocortisol OR Sapogenins OR Secosteroids OR Beclo-
methasone OR Chlormadinone OR Cyproterone OR Fluorinat-
ed OR Betamethasone OR Dexamethasone OR Flumethasone 
OR Fluocinolone OR Fluocortolone OR Fluorometholone OR 
Fluoxymesterone OR Fluprednisolone OR Flurandrenolone OR 
Flurogestone OR Paramethasone OR Triamcinolone OR Pred-
nisolone OR Hydrocortisone OR corticosteroids OR Mineralo-
corticoids OR Glucocorticoids OR Hydroxycorticosteroids) AND 
((clinical[Title/Abstract] AND trial[Title/Abstract]) OR clini-
cal trials[MeSH Terms] OR clinical trial[Publication Type] OR 
random*[Title/Abstract] OR random allocation[MeSH Terms] 
OR therapeutic use[MeSH Subheading])
Question 6
In which situations should continuous NSAID use be recom-
mended for patients with ankylosing spondylitis?
(Spondylitis, Ankylosing OR Bechterew’s Disease OR Anky-
losing Spondyloarthritis OR Rheumatoid Spondylitis OR Marie-
Struempell Disease) AND (Anti-Infl ammatory Agents OR Cyclo-
oxygenase 2 OR COX-2 OR rofecoxib OR Ibuprofen OR celecoxib 
OR Naproxen OR Acetaminophen OR NSAID OR paracetamol 
OR parecoxib OR diclofenac OR aspirin OR meloxicam OR 
acetylsalicylic OR piroxicam) AND (randomized controlled 
trial[Publication Type] OR (randomised[Title/Abstract] AND 
controlled[Title/Abstract] AND trial[Title/Abstract])) 
Question 7
What is the evidence for the use of conventional drugs (meth-
otrexate and sulfasalazine, among others) in patients with 
ankylosing spondylitis?
Spondylitis, Ankylosing OR Bechterew’s Disease OR Anky-
losing Spondyloarthritis OR Rheumatoid Spondylitis OR Ma-
rie-Struempell Disease AND (methotrexate OR lefl unomide 
OR sulfasalazine OR gold sodium OR hydroxychloroquine OR 
ciclosporin)
Question 8
What are the indications for the use of biological agents that 
block tumour necrosis factor (anti-TNF) in ankylosing spon-
dylitis?
Spondylitis, Ankylosing OR Bechterew’s Disease OR An-
kylosing Spondyloarthritis OR Rheumatoid Spondylitis OR 
Marie-Struempell Disease AND (Tumor Necrosis Factor-alpha 
OR golimumab OR infl iximab OR adalimumab OR etanercept)
Question 9
Is there a difference in effi cacy among anti-TNF drugs in pa-
tients with ankylosing spondylitis?
Spondylitis, Ankylosing OR Bechterew’s Disease OR An-
kylosing Spondyloarthritis OR Rheumatoid Spondylitis OR 
Marie-Struempell Disease AND (Tumor Necrosis Factor-alpha 
OR golimumab OR infl iximab OR adalimumab OR etanercept)
Question 10
Is there a difference in the safety among the anti-TNF drugs 
in patients with ankylosing spondylitis?
Spondylitis, Ankylosing OR Bechterew’s Disease OR An-
kylosing Spondyloarthritis OR Rheumatoid Spondylitis OR 
Marie-Struempell Disease AND (Tumor Necrosis Factor-alpha 
OR golimumab OR infl iximab OR adalimumab OR etanercept)
Question 11
Is the use of anti-TNF treatment capable of reducing struc-
tural damage in patients with ankylosing spondylitis?
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Spondylitis, Ankylosing OR Bechterew’s Disease OR An-
kylosing Spondyloarthritis OR Rheumatoid Spondylitis OR 
Marie-Struempell Disease AND (Tumor Necrosis Factor-alpha 
OR golimumab OR infl iximab OR adalimumab OR etanercept)
Question 12
Is there evidence for the effi cacy and safety of anti-TNF drugs 
in extra-articular manifestations in patients with ankylosing 
spondylitis?
(Spondylitis, Ankylosing OR Bechterew’s Disease OR An-
kylosing Spondyloarthritis OR Rheumatoid Spondylitis OR 
Marie-Struempell Disease) AND (Tumor Necrosis Factor-alpha 
OR golimumab OR infl iximab OR adalimumab OR etanercept) 
AND (Uveitis OR Iridocyclitis OR Cardiovascular Diseases OR 
Pulmonary Fibrosis OR Lung diseases OR Extra-articular OR 
Extra articular OR Infl ammatory Bowel Diseases OR psoriatic 
arthritis OR Psoriasis OR Crohn Disease OR bone)
Question 13
What is the evidence that supports the switch of anti-TNF 
agents in patients with ankylosing spondylitis?
Spondylitis, Ankylosing OR Bechterew’s Disease OR Anky-
losing Spondyloarthritis OR Rheumatoid Spondylitis OR Ma-
rie-Struempell Disease AND switch* AND (randomised con-
trolled trial[Publication Type] OR (randomised[Title/Abstract] 
AND controlled[Title/Abstract] AND trial[Title/Abstract]))
Question 14
How long should anti-TNF drugs be used in the follow up of a 
patient with ankylosing spondylitis?
(Spondylitis, Ankylosing OR Bechterew’s Disease OR An-
kylosing Spondyloarthritis OR Rheumatoid Spondylitis OR 
Marie-Struempell Disease) AND (Tumor Necrosis Factor-alpha 
OR golimumab OR infl iximab OR adalimumab OR etanercept)
Question 15
Is there evidence for the use of biological agents with other 
mechanisms of action in ankylosing spondylitis?
Spondylitis, Ankylosing OR Bechterew’s Disease OR An-
kylosing Spondyloarthritis OR Rheumatoid Spondylitis OR 
Marie-Struempell Disease AND (rituximab OR tocilizumab OR 
abatacept OR Antibodies, Monoclonal)
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